Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
Investors shouldn't count out Pfizer in the GLP-1 market just yet.
·
The Motley Fool
Bear Market Fears Are Back. History Says This Proven Strategy Can Protect Your Investments.
Keep your blinders on when possible.
·
The Motley Fool
Zcash Just Turned 10. Here’s What Could Be Coming for ZEC Investors Over the Next 10 Years.
This privacy coin is on a tear, and it could rival Bitcoin one day.
·
The Motley Fool
3 Things to Know if You Plan to Claim Social Security in 2027
Make sure you're on top of things before filing a claim.
·
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
Thursday's drop was historic. The popular growth investor went shopping.
·
The Motley Fool
If the Stock Market Crashes, I’m Loading Up on These 2 No-Brainer ETFs
Stocks sold off sharply on Nov. 5, potentially marking the start of a bear market.
·
The Motley Fool
These 3 Stocks Just Fell After Strong Earnings. Here’s the One I’d Buy Right Now
Shopify, Datadog and Palantir all topped expectations. Here's why investors sold, and the one I'd buy.
·
The Motley Fool